Riker's Tambocor (flecainide)
Executive Summary
According to FDA minutes of its Cardio-Renal Drugs Advisory Cmte. meeting in June, the cmte. recommended approval of Tambocor for use in "symptomatic ventricular arrhythmias" rather than "symptomatic sustained ventricular tachycardia" as reported ("The Pink Sheet" June 25, p. 12).
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.